Name: Candice
Wechat： 15360466377

Tel：+86 15360466377

Whatsapp:+8 52   61859189

Email： guangsheng 1 @zgguangsheng.com

FOXO4 -DRI is pretty much a peptide (short chains of compounds part of the amino group linked by peptide bonds) that is injected into your body. It then finds the gene FOXO4 (short for forkhead box O4) and interacts with it to stop any communication with the p53 gene, initiating apoptosis (the destruction of cells) in senescent cells.

Pls input...

Retatrutide —developed by pharmaceutical giant Eli Lilly and alternatively known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943—is an injectable breakthrough poised for FDA approval, with significant potential to treat obesity and diabetes. While it shares similarities with established weight loss therapies like tirzepatide and semaglutide, retatrutide delivers enhanced efficacy. When paired with balanced nutrition, consistent physical activity, and healthy lifestyle adjustments, it not only amplifies weight loss results but also addresses obesity-related comorbidities such as diabetes and hypertension (high blood pressure).

What sets retatrutide apart from other weight loss medications is its superior effectiveness, driven by three key therapeutic mechanisms:

**Gastric Inhibitory Polypeptide Receptor (GIPR) Agonism: By activating GIP receptors, retatrutide strengthens appetite control, blocks fat storage, reduces caloric intake, and boosts energy expenditure.
**Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonism: It supports weight reduction by improving glycemic control—stimulating pancreatic insulin secretion while curbing the release of glucagon, a hormone that elevates blood sugar levels.
**Glucagon Receptor (GR) Agonism**: Retatrutide further regulates blood glucose by suppressing glucagon release, diminishes food cravings, and increases energy burn, all of which contribute to meaningful weight loss.

Products Name : Retatrutide
Trade Name : LY-3437943
CAS No. :2381089-83-2
Molecular Formula : C221H342N46O68
Molecular Weight : 4731.33g/mol
Sequence:Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{ α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Appearance : White Lyophilized powder
Reconstitution:  Required 
Storage : After reconstitution store at 2°C - 8°C

BENEFITS OF GLP-1 AGONISTS

• Slows gastric emptying to prolong feelings of fullness
• Suppresses excessive hepatic glucose production (prevents the liver from overproducing sugar)
• Stimulates pancreatic insulin secretion in response to elevated blood glucose levels
• Aids in glycemic control and blood sugar regulation
• Alleviates hyperglycemia, particularly postprandial (after-meal) spikes
• Reduces fasting insulin concentrations and fasting blood glucose levels
• Lowers hemoglobin A1c (HbA1c) to improve long-term glycemic outcomes
• Curbs appetite and reduces caloric consumption, while counteracting weight gain
• Demonstrates efficacy in lowering triglyceride levels and mitigating oxidative stress associated with high LDL ("bad" cholesterol)
• Promotes weight loss in obese patients when administered at higher dosages
• Decreases leptin levels and enhances leptin sensitivity (improving the body’s ability to regulate hunger and metabolism)

Facilitates the browning of white adipose tissue (converts energy-storing white fat to energy-burning brown fat)

Pls input...